Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 8, 2017
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), today announced that it has dosed the first patient in a Phase ...
November 8, 2017
Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017
WALTHAM, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
November 8, 2017
Zealand Pharma: Interim report for the first nine months of 2017
Copenhagen, November 8, 2017 - Zealand Pharma A/S ("ZEAL") announces financial results and continued strong progress for its product candidates and business for the first ...
November 7, 2017
Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the third quarter ended ...
November 7, 2017
Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results
EMERYVILLE, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
November 7, 2017
Pernix Therapeutics Reports Third Quarter 2017 Financial Results
MORRISTOWN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today financial results ...
November 7, 2017
TRACON Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
November 7, 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Office
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 7, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
November 7, 2017
HTG Molecular Diagnostics Reports 2017 Third Quarter Earnings
TUCSON, Ariz., Nov. 07, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, ...
November 7, 2017
Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
AUSTIN, Texas, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino ...
November 7, 2017
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update
DUBLIN, Ireland , Nov.  07, 2017  (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization ...
November 7, 2017
TherapeuticsMD to Present at Two Upcoming Investor Conferences
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2017 Healthcare Conference on ...
November 7, 2017
VALNEVA Signs $39.6 Million IXIARO® Supply Contract with US Government
Lyon (France), November 7, 2017 - Valneva SE ("Valneva" or "the Company"),  a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines, ...
November 6, 2017
VALNEVA to Present at Jefferies and Stifel 2017 Healthcare Conferences
Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing innovative lifesaving vaccines, today ...
November 6, 2017
TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the ...
November 6, 2017
TherapeuticsMD Announces Third Quarter 2017 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (TXMD), an innovative women’s healthcare company, today announced its financial results for the quarter ended September 30, 2017. ...
November 6, 2017
VBL Therapeutics and NanoCarrier Co., Ltd. Sign Exclusive Agreement for VB-111 in Japan
TEL AVIV, Israel, Nov. 06, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
November 6, 2017
Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates
WALTHAM, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
November 6, 2017
Reata Provides Update on Bardoxolone Methyl from the American Society of Nephrology Kidney Week Meeting
IRVING, Texas, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (Reata or Company), a clinical-stage biopharmaceutical company, today provided an update on the ...
November 6, 2017
Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences
PALO ALTO, Calif., Nov. 6, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today ...
Page 80 of 117